OverviewSuggest Edit

Osmotica Pharmaceutical is a fully-integrated pharmaceutical company specializing in osmotic drug delivery. The Company possesses a diversified product portfolio in the specialty neurology and women's health space, including five promoted products and approximately 35 non-promoted products, several of which incorporate the proprietary Osmodex® drug delivery system. The non-promoted product portfolio includes methylphenidate HCl ER tablets and venlafaxine HCl ER tablets and prescription and non-prescription dietary supplements.

TypePublic
Founded2000
HQBridgewater, US
Websiteosmotica.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Dec 2018)466(+13%)
Job Openings19
Revenue (FY, 2018)$263.7 M(+11%)
Share Price (Feb 2020)$5.9 (-3%)

Key People/Management at Osmotica Pharmaceuticals

David Burgstahler

David Burgstahler

Director
Sriram Venkataraman

Sriram Venkataraman

Director
Show more

Osmotica Pharmaceuticals Office Locations

Osmotica Pharmaceuticals has offices in Bridgewater, Marietta, Sayreville, Tampa and in 4 other locations
Bridgewater, US (HQ)
400 Crossing Blvd
Marietta, US
895 Sawyer Rd
Sayreville, US
2500 Main Street Extension #6
Tampa, US
2631 Causeway Center Dr
Wilmington, US
1904 Eastwood Rd STE 205
Almagro, AR
821 Francisco Acuña de Figueroa
Show all (8)

Osmotica Pharmaceuticals Financials and Metrics

Osmotica Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Osmotica Pharmaceuticals's revenue was reported to be $263.70 m in FY, 2018
USD

Revenue (Q3, 2019)

65.5m

Gross profit (Q3, 2019)

38.1m

Gross profit margin (Q3, 2019), %

58.3%

Net income (Q3, 2019)

(112.7m)

EBIT (Q3, 2019)

(123.0m)

Market capitalization (21-Feb-2020)

343.7m

Closing stock price (21-Feb-2020)

5.9

Cash (30-Sept-2019)

98.0m

EV

517.5m
Osmotica Pharmaceuticals's current market capitalization is $343.7 m.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

170.5m237.7m263.7m

Revenue growth, %

39%

Cost of goods sold

125.6m125.2m135.0m

Gross profit

44.9m112.5m128.7m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

53.7m66.3m57.1m57.5m65.5m

Cost of goods sold

21.5m32.0m29.2m32.6m27.3m

Gross profit

32.3m34.3m27.9m24.9m38.1m

Gross profit Margin, %

60%52%49%43%58%
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

19.6m34.7m70.8m

Accounts Receivable

43.7m37.6m56.4m

Prepaid Expenses

9.5m25.8m20.7m

Inventories

19.8m17.0m24.4m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

32.2m63.1m63.7m98.0m

Accounts Receivable

72.7m56.9m68.1m33.9m

Prepaid Expenses

18.8m16.2m14.2m8.2m

Inventories

25.6m27.8m27.9m27.2m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(41.8m)(45.2m)(109.4m)

Depreciation and Amortization

23.6m46.5m81.6m

Inventories

12.6m2.9m(7.4m)

Accounts Payable

(14.4m)588.2k(11.3m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(42.3m)(3.6m)(6.2m)(130.9m)(244.3m)

Depreciation and Amortization

24.9m61.3m18.0m36.0m50.6m

Inventories

(132.9k)(8.6m)(3.4m)(3.5m)(2.9m)

Accounts Payable

(21.8m)(9.1m)(4.3m)(6.0m)(15.0m)
USDY, 2019

EV/EBIT

-4.2 x

EV/CFO

15.7 x

Financial Leverage

3.5 x
Show all financial metrics

Osmotica Pharmaceuticals Operating Metrics

Oct, 2018

Products

35
Show all operating metrics

Osmotica Pharmaceuticals Revenue Breakdown

Embed Graph

Osmotica Pharmaceuticals revenue breakdown by business segment: 9.4% from Lorzone, 7.8% from Divigel, 40.4% from Venlafaxine ER, 18.4% from Methylphenidate and 24.0% from Other

Osmotica Pharmaceuticals Online and Social Media Presence

Embed Graph

Osmotica Pharmaceuticals News and Updates

Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors

BRIDGEWATER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced the appointment of Michael J. DeBiasi to the Company’s Board of Directors, effective as of October 1, 2019.

Osmotica Pharmaceuticals plc Announces Results of Extraordinary General Meeting

BRIDGEWATER, N.J., Sept. 4, 2019 /PRNewswire/ -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced results of the Company's Extraordinary General Meeting. At the Extraordinary General Meeting of the...

Osmotica Pharmaceuticals plc to Provide Second Quarter 2019 Business and Financial Update on August 8, 2019

BRIDGEWATER, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 second quarter financial results on Thursday, August 8, 2019, after t…

Osmotica Pharmaceuticals plc to Present at Jefferies 2019 Global Healthcare Conference

BRIDGEWATER, N.J., May 30, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn,…

Osmotica Pharmaceuticals plc to Present at 2019 RBC Capital Markets Global Healthcare Conference

BRIDGEWATER, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn,…

Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 (“RVL”) for Acquired Blepharoptosis (ptosis or droopy eyelid)

- Second Phase III Study 202 Meets Primary Endpoint; Provides Additional Evidence of Efficacy and Safety -
Show more

Osmotica Pharmaceuticals Frequently Asked Questions

  • When was Osmotica Pharmaceuticals founded?

    Osmotica Pharmaceuticals was founded in 2000.

  • Who are Osmotica Pharmaceuticals key executives?

    Osmotica Pharmaceuticals's key executives are David Burgstahler and Sriram Venkataraman.

  • How many employees does Osmotica Pharmaceuticals have?

    Osmotica Pharmaceuticals has 466 employees.

  • What is Osmotica Pharmaceuticals revenue?

    Latest Osmotica Pharmaceuticals annual revenue is $263.7 m.

  • What is Osmotica Pharmaceuticals revenue per employee?

    Latest Osmotica Pharmaceuticals revenue per employee is $565.9 k.

  • Who are Osmotica Pharmaceuticals competitors?

    Competitors of Osmotica Pharmaceuticals include Horizon Therapeutics, Esperion Therapeutics and Vitality Biopharma.

  • Where is Osmotica Pharmaceuticals headquarters?

    Osmotica Pharmaceuticals headquarters is located at 400 Crossing Blvd, Bridgewater.

  • Where are Osmotica Pharmaceuticals offices?

    Osmotica Pharmaceuticals has offices in Bridgewater, Marietta, Sayreville, Tampa and in 4 other locations.

  • How many offices does Osmotica Pharmaceuticals have?

    Osmotica Pharmaceuticals has 8 offices.